SAVA Q2 2024 Earnings — Cassava Sciences, Inc. Revenue & Financial Results | Market Cap Arena

SAVACassava Sciences, Inc.

$116M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$15M

Operating Income

-$61M

Net Income

$6M

EPS (Diluted)

$0.13

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$244M

Total Liabilities

$55M

Stockholders' Equity

$189M

Cash & Equivalents

$207M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$15M	-$392,000	-3777.0%
Operating Income	-$61M	-$29M	-113.4%
Net Income	$6M	-$26M	+123.3%